Evaluation of N-(phenylmethyl)-4-[5-(phenylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-4-yl]benzamide inhibitors of Mycobacterium tuberculosis growth

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 10, 2007, Pages 2740-2744

  Wall, Michael D ^a   Oshin, Michael ^a   Chung, Gavin A C ^a   Parkhouse, Tony ^a   Gore, Andrea ^a   Herreros, Esperanza ^b   Cox, Brian ^a   Duncan, Ken ^a   Evans, Brian ^a   Everett, Martin ^a   Mendoza, Alfonso ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (Spain)

Author keywords

Imidazopiperidines; InhA; Mycobacterium tuberculosis

Indexed keywords

FAS LIGAND; IMIDAZOPIPERIDINE; N (PHENYLMETHYL) 4 [5 (PHENYLMETHYL) 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDIN 4 YL]BENZAMIDE INHIBITOR; PIPERIDINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL STRAIN; CELL ACTIVITY; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; BENZAMIDES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; PIPERIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

MYCOBACTERIUM TUBERCULOSIS;

EID: 34247347420     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.02.078     Document Type: Article

References (42)

1. Current WHO initiatives to combat TB can be viewed on the following websites; (a) http://www.stoptb.org/stop_tb_initiative/.
2. http://www.theglobalfund.org/en/.
3. Raviglione M.C. Tuberculosis 83 (2003) 4
4. Espinal M.A. Tuberculosis 83 (2003) 44
5. Tuberculosis, HIV/Aids and Malaria, The status and impact of the three diseases. WHO, Geneva (2005), report which is available on the following website: .
6. Groups at Risk: WHO report on the tuberculosis epidemic. WHO, Geneva (1996). This report is available on the following website: .
7. Gupta R. Int. J. Tuberc. Lung. Dis. 7 (2003) 410
8. Dessen A., Quemard A., Blanchard J.S., Jacobs W.R., and Sacchettini J.C. Science 267 (1995) 1638
9. Quemard A., Sacchettini J.C., Dessen A., Vilcheze C., Bittman R., Jacobs W.R., and Blanchard J.S. Biochemistry 34 (1995) 8235
10. Brennan P.J., and Nikaido H. Annu. Rev. Biochem. 64 (1995) 29
11. Lee R.E., et al. Curr. Top. Microbiol. Immunol. 215 (1996) 1
12. Rozwarski D.A., Grant G.A., Barton D.H.R., Jacobs W.R., and Sacchettini J.C. Science 279 (1998) 98
13. Parikh S.L., Xiao G., and Tonge P.J. Biochemistry 39 (2000) 26, 7645
14. Vilcheze C., Morbidoni H.R., Weisbrod T.R., Iwamoto H., Sacchettini J.C., and Jacobs W.R. J. Bacteriol. 182 (2000) 4059
15. Schroeder E.K., de Souza O.N., Santos D.S., Blanchard J.S., and Basso L.A. Curr. Pharm. Biotechnol. 3 (2002) 197
16. Sacchettini J.C., and Blanchard J.S. Res. Microbiol. 147 (1996) 36
17. Quemard A., Dessen A., Sugantino M., Jacobs W.R., Sacchettini J.C., and Blanchard J.S. J. Am. Chem. Soc. 118 (1996) 1561
18. Stoeckle M.Y., et al. J. Infect. Dis. 168 (1993) 1063
19. Heym B., et al. Lancet 344 (1994) 293
20. Heym B., et al. Mol. Microbiol. 15 (1995) 235
21. Cockerill F.R., et al. J. Infect. Dis. 171 (1995) 240
22. Kapur V., et al. Arch. Pathol. Lab. Med. 119 (1995) 131
23. Rouse D.A., et al. Antimicrob. Agents Chemother. 39 (1995) 2472
24. Musser J.M., et al. J. Infect. Dis. 173 (1996) 196
25. Telenti A., et al. J. Clin. Microbiol. 35 (1997) 719
26. Heym B., and Cole S.T. Res. Microbiol. 143 (1992) 721
27. Cockerill F.R., Uhl J.R., Temesgen Z., Zhang Y., Stockman L., Roberts G.D., Williams D.L., and Kline B.C. J. Infect. Dis. 171 (1995) 240
28. Haym B., Alzari P.M., Honore N., and Cole S.T. Mol. Microbiol. 15 (1995) 235
29. Musser J.M., Kapur V., Williams D.L., Krieswirth B.N., Soolingen D.V., and van Embden J.D.A. J. Infec. Dis. 173 (1996) 196
30. Stocker F.B., Fordice M.W., Larson J.K., and Thorstenson J.H. J. Org. Chem. 31 (1966) 7, 238
31. Stocker F.B., and Evans A.J. J. Org. Chem. 55 (1990) 3370
32. -1 and detection at λ = 215 nm, fractions were collected using an ethanol/heptane gradient up to 30% ethanol (over 15 min) to give the separation of the enantiomers 9a-d.
33. A range of aldehydes were chosen from work carried out on docking within the InhA active site, pharmacophore generation and best fit models.
34. Data for these analogues have been omitted.
35. -1 PMS and 0.3 M urea in PBS buffer.
36. -1 for S. aureus ATCC 29213.
37. -1.
38. We use an in-house assay for determination of compounds which are likely to behave in an non-specific fashion, the results of which complement the work of. McGovern S.L., Caselli E., Grigorieff N., and Shoichet B.K. J. Med. Chem. 45 8 (2002) 1712
39. McGovern S.L., Helfand B.T., Feng B., and Shoichet B.K. J. Med. Chem. (2003)
40. Seidler J., McGovern S.L., Thompson D.N., and Shoichet B.K. J. Med. Chem. (2003) 4477
41. Feng Y.B., and Shoichet K.B. J. Med. Chem. 49 (2006) 2151
42. Ryan A.J., Gray N.M., Lowe P.N., and Chung C.-W. J. Med. Chem. 46 (2003) 3448